Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 195.05

-0.4%

Dec 29 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (29275)	9/13/1999 6:43:00 PM
From: Henry Niman	Read Replies (1) of 32384

Phase II Clinical trial using daclizumab for autoimmune indications: Developer: Protein Design Labs Indication: Prevention of kidney transplant rejection episodes - cyclosporine elimination Marketer(s): Hoffman-La Roche Product: daclizumab + mycophenolate mofetil + corticosteroids Current Status: Phase II Tradename: Zenapax + CellCept Active Agreement(s): Disease: Autoimmune - Immunosuppressives, Transplantation Terminated Agreement(s): Technology: Monoclonals - Humanized Abs

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next